HRP20211017T1 - Poboljšani cd31 peptidi - Google Patents

Poboljšani cd31 peptidi Download PDF

Info

Publication number
HRP20211017T1
HRP20211017T1 HRP20211017TT HRP20211017T HRP20211017T1 HR P20211017 T1 HRP20211017 T1 HR P20211017T1 HR P20211017T T HRP20211017T T HR P20211017TT HR P20211017 T HRP20211017 T HR P20211017T HR P20211017 T1 HRP20211017 T1 HR P20211017T1
Authority
HR
Croatia
Prior art keywords
peptide
seq
amino acid
acid sequence
peptide according
Prior art date
Application number
HRP20211017TT
Other languages
English (en)
Croatian (hr)
Inventor
Giuseppina Caligiuri
Antonino Nicoletti
Original Assignee
Institut National De La Santé Et De La Recherche Médicale (Inserm)
Université de Paris
Assistance Publique - Hôpitaux De Paris
Universite Paris 13 - Paris Nord
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Institut National De La Santé Et De La Recherche Médicale (Inserm), Université de Paris, Assistance Publique - Hôpitaux De Paris, Universite Paris 13 - Paris Nord filed Critical Institut National De La Santé Et De La Recherche Médicale (Inserm)
Publication of HRP20211017T1 publication Critical patent/HRP20211017T1/hr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Rheumatology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
HRP20211017TT 2012-06-19 2013-06-19 Poboljšani cd31 peptidi HRP20211017T1 (hr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP12305697 2012-06-19
PCT/EP2013/062806 WO2013190014A1 (en) 2012-06-19 2013-06-19 Improved cd31 peptides
EP13729753.7A EP2861241B1 (en) 2012-06-19 2013-06-19 Improved cd31 peptides

Publications (1)

Publication Number Publication Date
HRP20211017T1 true HRP20211017T1 (hr) 2021-10-01

Family

ID=48652100

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20211017TT HRP20211017T1 (hr) 2012-06-19 2013-06-19 Poboljšani cd31 peptidi

Country Status (11)

Country Link
US (1) US10815272B2 (enExample)
EP (1) EP2861241B1 (enExample)
JP (1) JP6357470B2 (enExample)
DK (1) DK2861241T3 (enExample)
ES (1) ES2877513T3 (enExample)
HR (1) HRP20211017T1 (enExample)
HU (1) HUE055593T2 (enExample)
PL (1) PL2861241T3 (enExample)
PT (1) PT2861241T (enExample)
SI (1) SI2861241T1 (enExample)
WO (1) WO2013190014A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109069586A (zh) * 2016-03-21 2018-12-21 国家健康与医学研究院 用于再灌注损伤的预防和/或治疗的cd31shed激动剂
JP7166512B2 (ja) * 2016-05-03 2022-11-08 インスティチュート ナショナル デ ラ サンテ エ デ ラ ルシェルシュ メディカル （インセルム） 炎症のイメージングのための分子標識としてのＣＤ３１ｓｈｅｄ
US20220001083A1 (en) * 2018-11-27 2022-01-06 Balt Extrusion Method for the modification of a device surface by grafting a cd31-derived peptide onto the surface of said device
WO2020109833A1 (en) 2018-11-27 2020-06-04 Institut National De La Sante Et De La Recherche Medicale (Inserm) Method for the modification of a substrate surface by grafting a peptide onto the surface of said substrate
WO2023099932A1 (en) * 2021-12-03 2023-06-08 INSERM (Institut National de la Santé et de la Recherche Médicale) Cd31 mimetic coating for endovascular stent

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6087331A (en) 1990-01-19 2000-07-11 The Blood Center Of Southeastern Wisconsin Therapeutic use of platelet-endothelial cell adhesion molecule-1 compositions
JP3914988B2 (ja) * 2003-08-06 2007-05-16 国立大学法人名古屋大学 細胞死誘導のためのペプチドおよび医薬
EP2313432B1 (en) * 2008-06-30 2017-09-13 Institut National de la Sante et de la Recherche Medicale (INSERM) Use of cd31 peptides in the treatment of thrombotic and autoimmune disorders
WO2013152919A1 (en) 2012-04-11 2013-10-17 Institut National De La Sante Et De La Recherche Medicale (Inserm) Detection of platelet-derived shed cd31

Also Published As

Publication number Publication date
SI2861241T1 (sl) 2021-11-30
JP2015521611A (ja) 2015-07-30
EP2861241A1 (en) 2015-04-22
PL2861241T3 (pl) 2021-10-25
US20150203536A1 (en) 2015-07-23
EP2861241B1 (en) 2021-04-28
ES2877513T3 (es) 2021-11-17
DK2861241T3 (da) 2021-07-05
JP6357470B2 (ja) 2018-07-11
HUE055593T2 (hu) 2021-12-28
PT2861241T (pt) 2021-07-02
US10815272B2 (en) 2020-10-27
WO2013190014A1 (en) 2013-12-27

Similar Documents

Publication Publication Date Title
HRP20211017T1 (hr) Poboljšani cd31 peptidi
Wang et al. Influence of peptide characteristics on their stability, intestinal transport, and in vitro bioavailability: A review
ES2927977T3 (es) Moduladores peptídicos de la interacción entre el péptido C humano y el receptor de elastina humana para uso terapéutico
Ryan et al. Bioactive peptides from muscle sources: meat and fish
EP2875824B1 (en) Composition for preventing or treating cachexia
Rigogliuso et al. Recovery of bioactive compounds from marine organisms: focus on the future perspectives for pharmacological, biomedical and regenerative medicine applications of marine collagen
HRP20140616T1 (hr) Peptidni analog oksintomodulina
HRP20161807T1 (hr) Produljeni rekombinantni polipeptidi i sastavi koji ih sadrže
Zhao et al. Simulated gastrointestinal digest from preserved egg white exerts anti-inflammatory effects on Caco-2 cells and a mouse model of DSS-induced colitis
HRP20170482T1 (hr) Sintetski peptidoglikani koji vežu hijaluronsku kiselinu, dobivanje, i postupci uporabe
HRP20161608T1 (hr) Modificirani tuberkulozni antigeni
HRP20200503T1 (hr) Fuzijski proteini
RU2014103288A (ru) Слитые полипептиды релаксина и их применение
NZ602522A (en) Biosynthetic proline/alanine random coil polypeptides and their uses
CN102256999A (zh) 向白细胞的有效转运
WO2008149143A3 (en) Methods for selecting protease resistant polypeptides
DK2162462T3 (da) Cxc-chemokin-receptor-4 (cxcr4) antagonistisk polypeptid
JP2017522362A5 (enExample)
JP2015534972A5 (enExample)
JP2017520514A (ja) 臓器、組織又は細胞移植用組成物、キット及び移植方法
HRP20160547T1 (hr) Pegilirani apelin i njegova upotreba
RU2014140231A (ru) Антимикробные пептиды
EP4306123A3 (en) Saposin-a derived peptides and uses thereof
JP2015521611A5 (enExample)
ES2685987T3 (es) Análogos de péptidos gip